摘要
目的 :通过大肠埃希菌原核表达体系,分别获得轮状病毒疫苗Rotateq及Rotarix的VP8*基因表达产物,为深入研究轮状病毒VP8*蛋白的结构和功能奠定基础。方法 :基因合成轮状病毒疫苗Rotateq及Rotarix的P[8]型VP8*基因序列,将其克隆到携带有GST标签的pGEX-4T1表达载体中构建重组质粒pGEX-4T1-VP8*,测序正确后转化大肠杆菌BL21(DE3),通过SDS-PAGE电泳检测表达产物,并通过Glutathione Sepharose 4B纯化柱进行纯化,Western Blot鉴定。结果 :SDS-PAGE电泳结果显示分子量52KD处有深染带,Western-Blot显示该处蛋白能与GST标签抗体结合。结论 :成功构建了包含Rotateq及Rotarix VP8*基因的重组表达载体pGEX-4T1-VP8*,获得了可溶性GST-VP8*重组蛋白。
Objective To obtain Rotavirus vaccine Rotateq and Rotari VP8~* gene expression products by E. coli prokaryotic expression system, further study of rotavirus VP8~* protein structure and function of the foundation. Method Synthesis Rotateq and Rotarix rotavirus vaccine type P [8] VP8~* gene sequences, to clone it to Pgex-4 T1 with GST tags in the expression vector to construct recombinant plasmid, After sequencing confirmed then transformation into E. coli BL21(DE3). SDS-PAGE detection of the expression products, purification by glutathione sepharose 4 B purification column and identification by western blot.Results SDS-PAGE results showed that the molecular weight of 52 KD with hyperchromatic, western blot shows it protein can combine with GST label antibody. Conclusion Successfully built recombinant expression vector Pgex-4 T1-VP8~* which contains Rotateq and Rotarix VP8~* gene, and obtained soluble GST-VP8~* recombinant proteins successful.
引文
[1]Parashar U. D, E. G. Hummelman, J. S. Bresee, et al. Global illness and deaths caused by rotavirus disease in children[J]. Emerg Infect Dis,2003, 9(5):565-572.
[2]Kapikian A. Z. A rotavirus vaccine for prevention of severe diarrhoea of infants and young children:development, utilization and withdrawal[J].Novartis Found Symp, 2001, 238:171-179.
[3]Estes M. K, G. Kang, C. Q. Zeng, et al. Pathogenesis of rotavirus gastroenteritis[J]. Novartis Found Symp, 2001, 238:82-100.
[4]LopezS, C. F. Arias. Multistep entry of rotavirus into cells:a Versaillesque dance[J]. Trends Microbiol, 2004, 12(6):271-278.
[5]Arias C. F, P. Romero, V. Alvarez, et al. Trypsin activation pathway of rotavirus infectivity[J]. J Virol, 1996, 70(9):5832-5839.
[6]Clark S. M, J. R. Roth, M. L. Clark, et al. Trypsin enhancement of rotavirus infectivity:mechanism of enhancement[J]. J Virol, 1981, 39(3):816-822.
[7]Espejo R. T, S. Lopez, C. Arias. Structural polypeptides of simian rotavirus SA11 and the effect of trypsin[J]. J Virol, 1981, 37(1):156-160.
[8]Estes M. K, D. Y. Graham, B. B. Mason. Proteolytic enhancement of rotavirus infectivity:molecular mechanisms[J]. J Virol, 1981, 39(3):879-888.
[9]Lopez S, C. F. Arias, J. R. Bell, et al. Primary structure of the cleavage site associated with trypsin enhancement of rotavirus SA11 infectivity[J].Virology, 1985, 144(1):11-19.
[10] Crawford S. E, S. K. Mukherjee, M. K. Estes, et al. Trypsin cleavage stabilizes the rotavirus VP4 spike[J]. J Virol, 2001, 75(13):6052-6061.
[11] Tate J. E, BurtonA. H, Boschi-pinto C, et al.2008Estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes:a systematic review and meta-analysis[J]. Lancet Infectious Diseases,2012, 12(2):136-41.
[12] Word Health Organization. Rotavirus vaccines:an update[J]. Wkly epidemiol Rec, 2009, 84(50):533-40.
[13] Word Health Organization. Rotavirus vaccines WHO position paper January 2013[J]. Wkly epidemiol Rec, 2013, 88(5):4-64.
[14]李丹地,徐子乾,谢广成,等.确认我国轮状病毒疫苗株LLR基因型为G10P[15][J].病毒学报, 2015:170-173.